Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Retrospective, Pivotal Study to Evaluate the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity Using MR Brain Images(Including T1 Weighted MRI and T2 FLAIR MRI) and Clinical Information (Age, Sex, APOE(apolipoproteinE) Genotype) in Mild Cognitive Impairment Patients

NCT05383053 is registered in ClinicalTrials.gov with Neurozen Inc. as lead sponsor.

NCT NCT05383053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05383053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Retrospective, Pivotal Study to Evaluate the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity Using MR Brain Images(Including T1 Weighted MRI and T2 FLAIR MRI) and Clinical Information (Age, Sex, APOE(apolipoproteinE) Genotype) in Mild Cognitive Impairment Patients
Lead sponsor
Neurozen Inc.
Phase
Observational
Overall status
Completed
Start date
July 22, 2022
Completion date
September 8, 2022
Enrollment
227 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, mild cognitive impairment